Use of Drugs for ADHD Among Adults: A Multinational Study Among 15.8 Million Adults in the Nordic Countries
The use of ADHD drugs among adults is controversial and has until recently not been approved for use in adults in most countries. The aim was to investigate use of ADHD drugs (stimulants and atomoxetine) among the entire adult population in the Nordic countries.
We conducted a multinational population-based prescription register study based on the entire adult population in the five Nordic countries (Denmark, Finland, Iceland, Norway and Sweden). All users of ADHD drugs aged 18-64 years during 2008-2012 were included, which for 2012 comprised 76,896 drug users among 15.8 million adult inhabitants.
Annual prevalence of drug use increased during the study period for both genders and all age groups. The overall prevalence increased from 2.4 to 5.3 per 1000 men and 1.8 to 4.4 per 1000 women. Incidence also increased, but to a lesser extent in the last part of the study period. Methylphenidate was used by 88 % of drug users. Treatment was discontinued within the first year by 21 % of new drug users. Among all users of ADHD drugs, 53 % of men and 64 % of women concurrently used other psychotropic drugs, most frequently antidepressants and hypnotics. Psychotropic co-medication increased with age and was more pronounced among women than men.
Use of ADHD drug among adults more than doubled over a 5-year period, and a majority were concurrently treated with other psychotropics. Adults constitute a substantial proportion of persons treated with ADHD drugs. Thus, evidence for long-term efficacy and safety in adults is urgently needed.
Øystein Karlstad, Helga Zoëga, Kari Furu, Shahram Bahmanyar, Jaana E Martikainen, Helle Kieler, Anton Pottegård
- Vertaisarvioitu: kyllä.
- Avoin saatavuus: kyllä.
- Koko viite: Karlstad, Ø., Zoëga, H., Furu, K., Bahmanyar, S., Martikainen, J. E., Kieler, H., & Pottegård, A. (2016). Use of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries. European journal of clinical pharmacology, 72(12), 1507–1514. https://doi.org/10.1007/s00228-016-2125-y